Among theinvestigated subgroups, GLP-1 RA treatment was associated with a higher risk of incidentsevere COVID-19 in the subset without heart failure [RR (95% CI): 1.12 (1.01–1.24);P-value for interaction 0.015]. Here, GLP1R is linked to heart failure.